Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

148.77
+2.031.38%
Pre-market: 148.770.00000.00%06:37 EDT
Volume:4.63M
Turnover:685.63M
Market Cap:184.58B
PE:-56.89
High:148.94
Open:146.60
Low:145.58
Close:146.74
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.74
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.16%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.60
PE(LYR):21.94

Loading ...

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

Gilead price target lowered to $145 from $155 at Barclays

TIPRANKS
·
Jul 29

Movement Alert|Gilead Sciences Overnight Rise 3.46%, Earnings Expectations and Oncology Pipeline Catalysts Drive Momentum

Market Focus
·
Jul 29

Earning Preview: Gilead Sciences revenue is expected to increase by 6.13%, and institutional views are bullish

Earnings Agent
·
Jul 29

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

Movement Alert|Gilead Sciences Rises 3.13% in Regular Trading, Biotech Sector Rally and Earnings Optimism Fuel Gains

Market Focus
·
Jul 28

Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating

MT Newswires Live
·
Jul 28

Gilead Sciences is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 28

Gilead price target lowered to $165 from $166 at Morgan Stanley

TIPRANKS
·
Jul 27

Gilead Sciences (GILD) Gets a Hold from RBC Capital

TIPRANKS
·
Jul 25

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 25

Moderna Inc. Stock Falls 5.2%, Underperforms Peers

Dow Jones
·
Jul 25

Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer

MT Newswires Live
·
Jul 24

Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

TIPRANKS
·
Jul 24

EMA CHMP Backs Gilead Trodelvy-keytruda Combo for First-line Pd-l1+ Metastatic TNBC

Reuters
·
Jul 24

Chmp Recommends Gilead’s Trodelvy® Plus Keytruda® in Pd-(l)1-positive First-line Metastatic Triple-negative Breast Cancer

THOMSON REUTERS
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating

MT Newswires Live
·
Jul 23

U.S. Research Roundup-alphabet, IBM, Tesla

Reuters
·
Jul 23

Gilead : Leerink Partners Cuts Target Price to $126 from $127

THOMSON REUTERS
·
Jul 23